- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
RESTYLANE STUDIED
Restylane, a new facial filler, may soon be FDA approved. In a study of 2,241 Brazilian patients conducted by Drs. Stephen Bosniak and Marian Cantisano-Zilkha between 1996 and 2001, patients who were treated with Restylane were found to have virtually no allergic reactions.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Case 2: Poorly Managed GPP Flares and Effisayil 2 Trial Results
Case 1: Experts on a GPP Emergency Case and Effisayil 1 Trial Results
Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis
Determining Appropriate Candidates for JAK Inhibitor Therapy
Enhancing Treatment Adherence: The Impact of Convenience and Topical JAK Inhibitors on Real-World Outcomes
Potential Role of Ruxolitinib Cream in Managing Pediatric Atopic Dermatitis: A Perspective on Use in Ages 2–11
The Need for Nonsteroidal Alternatives in Long-Term Atopic Dermatitis Care: A Focus on Pediatric Patients
Parental Frustrations with Current Treatment Options for Children with Atopic Dermatitis
Navigating Patient Factors When Deciding Treatment for a 38-Year-Old Woman With Severe Atopic Dermatitis
Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis
Related Content
